about
Overwhelming septic cavernous sinus thrombosis in a woman after combination of high-dose steroid and intravenous cyclophosphamide therapy for lupus nephritisContribution of renal biopsy data in predicting outcome in lupus nephritis. Analysis of 116 patients.Preserving ovarian function in patients receiving cyclophosphamide.Auricular chondritis and diffuse proliferative glomerulonephritis in primary Sjögren's syndrome.Short term effects of intravenous pulses of cyclophosphamide in the treatment of connective tissue disease crisis.New approaches to treating systemic lupus erythematosusRisk factors for serious infection during treatment with cyclophosphamide and high-dose corticosteroids for systemic lupus erythematosus.Severity of systemic lupus erythematosus with diffuse proliferative glomerulonephritis and the ineffectiveness of standard pulse intravenous cyclophosphamide therapy in Jamaican patients.Immunosuppressive treatment in severe connective tissue diseases: effects of low dose intravenous cyclophosphamide.Enhanced MHC class II expression in renal proximal tubules precedes loss of renal function in MRL/lpr mice with lupus nephritisAnalysis of T cells and major histocompatibility complex class I and class II mRNA and protein content and distribution in antiglomerular basement membrane disease in the rabbit.Modulation of renal disease in autoimmune NZB/NZW mice by immunization with bacterial DNA.Short course of weekly low-dose intravenous pulse cyclophosphamide in the treatment of lupus nephritis: a preliminary study.The evolution of drug discovery in systemic lupus erythematosus.Systemic lupus erythematosus. How to manage this chronic, complicated disorder.Remission of lupus nephritis with cyclophosphamide and late relapses following therapy withdrawal.Preservation of fertility and ovarian function and minimizing gonadotoxicity in young women with systemic lupus erythematosus treated by chemotherapy.End-stage renal disease in lupus: disease activity, dialysis, and the outcome of transplantation.Plasmapheresis and subsequent pulse cyclophosphamide versus pulse cyclophosphamide alone in severe lupus: design of the LPSG trial. Lupus Plasmapheresis Study Group (LPSG).Investigational drug therapies of treatment of multiple sclerosis.Clinical immunology.Flaxseed in lupus nephritis: a two-year nonplacebo-controlled crossover study.Renal biopsy in pregnancies complicated by undetermined renal disease.Risk factors for ovarian failure in patients with systemic lupus erythematosus.Use of intravenous pulsed cyclophosphamide in severe, generalized myasthenia gravis.Factors associated with chronic renal failure in 121 patients with diffuse proliferative lupus nephritis: a case-control study.Predictors of poor renal outcome in patients with lupus nephritis treated with combined pulses of cyclophosphamide and methylprednisolone.Soluble interleukin-2 receptors in systemic lupus erythematosus.Central nervous system lupus and pregnancy: 11-year experience at a single center.Value of finger arterial blood pressure in diagnosis of vascular changes in some connective tissue diseases.Ovarian failure in SLE patients using pulse cyclophosphamide: comparison of different regimes.Long term follow-up of patients with systemic lupus erythematosus.Improved strategies for designing lupus trials with targeted therapies: learning from 65 years of experience.Outcome of renal transplantation in ninety-seven cyclosporine-era patients with systemic lupus erythematosus and matched controls.
P2860
Q28373008-BEA7EE3B-541E-4873-8B8D-F04EA0912D29Q30630146-581CCD3C-8513-430B-9FC5-DB8276AF2721Q33534662-984B8F17-C0D3-4FAA-B1B3-0E2038187FC5Q33561955-63C37011-C702-41E9-957E-07427424E7BAQ33564864-286BB912-A926-4CB2-90FE-73928C4DBAEFQ33614633-3CF666C0-A286-4815-92E4-FFF823287A65Q34398069-C5C007AF-3C9D-4CE8-822F-6CB94003F85EQ35208185-E10926E0-E798-4097-9AC5-53BC4A0A522AQ35547376-B780955C-F461-4300-8BCB-DA8A73662D50Q35816089-AA0D6CB9-24D1-4594-A25A-38ECF06C7285Q35831193-9B610001-715C-4E91-A460-D8BD2955C961Q36366341-39D6D3EE-5051-47C1-9B00-6ACDE942E61AQ37153391-3BBC039E-1481-456D-B5E8-C159565DE07CQ38540167-A99B2542-B8A1-41BF-B7AC-A4BB1FDC579FQ38726894-446C1D65-2018-4A5E-8223-72E72A34126FQ40664132-9029F910-1193-4DD5-8772-1715D9C71150Q40748681-A226BB5F-C9FB-4588-A306-B65FF17B4ACBQ40829252-F7E97209-EE02-4050-8E52-81AF7B48A4E7Q41187058-4DCF92C8-A6D0-48B7-80A6-6C054D3A8B66Q41622019-1C455A11-6AAA-4BBE-82BB-6BAD331D5C4CQ41843290-0FC69E94-F2AC-46A6-9E66-192DCDEE2DD8Q43605403-6C768E04-EABA-4BDD-9319-CDCC1B252142Q43753194-4C48829E-CF9F-4402-90D0-CC808C1018DFQ43805549-0C719287-D626-4590-B98B-72A9B16B1E00Q44062952-1589B283-9755-406C-8B02-77A929D6A0D6Q44112212-03FD3671-0565-4873-B26D-B9A0AD4B7683Q44428095-025AEFC5-32CA-4159-9744-52442EC0BA69Q44557817-427E4E23-EB81-4ADB-A86B-11704BF808C7Q46263859-A417A610-B42B-4A20-BCC2-B36D3AFF4C99Q46455274-B48B2E37-39FE-4C47-95D8-AB7A6732193FQ46925234-164F9DF3-6267-4EB0-A2E2-64659F1F7F3FQ47798203-FE6069D3-1C74-4958-AB3A-6F2FB84D4CBFQ50493859-A4551E59-7FF2-48A4-821A-EEEA68F46644Q50870607-185CEB1D-94C9-4166-AAA8-9F74A8A43C97
P2860
description
1987 nî lūn-bûn
@nan
1987 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
1987 թվականի հունվարին հրատարակված գիտական հոդված
@hy
1987年の論文
@ja
1987年学术文章
@wuu
1987年学术文章
@zh-cn
1987年学术文章
@zh-hans
1987年学术文章
@zh-my
1987年学术文章
@zh-sg
1987年學術文章
@yue
name
NIH conference. Lupus nephritis.
@ast
NIH conference. Lupus nephritis.
@en
NIH conference. Lupus nephritis.
@nl
type
label
NIH conference. Lupus nephritis.
@ast
NIH conference. Lupus nephritis.
@en
NIH conference. Lupus nephritis.
@nl
prefLabel
NIH conference. Lupus nephritis.
@ast
NIH conference. Lupus nephritis.
@en
NIH conference. Lupus nephritis.
@nl
P2093
P1476
NIH conference. Lupus nephritis.
@en
P2093
Antonovych TT
Austin HA 3rd
Klippel JH
Steinberg AD
P356
10.7326/0003-4819-106-1-79
P407
P577
1987-01-01T00:00:00Z